<DOC>
	<DOCNO>NCT03090984</DOCNO>
	<brief_summary>Every patient include study undergo 3 standardised hemodialysis treatment , use different dialysis membrane ( PMMA , PS , AN69ST ) . The order membrane use randomize . During conventional standardised hemodialysis treatment , 6 blood sample take different time point ( T0 , T5 , T15 , T30 , T90 , T240 ) evaluate coagulation activation ( TAT , PF1+2 , d-dimers , TF ) , specifically , activation contact phase pathway coagulation ( kallikrein , fXIa , fXIIa ) .</brief_summary>
	<brief_title>Evaluation Contact Phase Activation During Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Patients treat hemodialysis since least three month . Hemodialysis treatment schedule 3 x 4 hour weekly . Arteriovenous fistula ( AVF ) use vascular access . Treatment oral acetylsalicylic acid 80 100mg q every day . ≥ 18 year age . Patients able agree provide sign informed consent . Use vitamin K antagonist novel oral anticoagulant therapy . Use chronic heparin treatment , UFH LMWH . Use clopidogrel . Use ACEinhibitors . Known allergy one dialysis membrane use study ( PMMA : BKU® , Toray ; PS : Phylter® , Bellco ; AN69ST : Evodial® , Gambro ) . Known heparininduced trombopenia type 2 . Active infection and/or ongoing systemic antimicrobial treatment . Presence central venous catheter , tunnel nontunnelled and/or AV graft . Hospitalized patient . Planned surgery study period . Mean Qb &lt; 300ml/min one last 3 dialysis session inclusion . Vascular access dysfunction define ( ) know AV access outflow tract stenosis , ( b ) plan vascular access intervention , ( c ) plan vascular access conversion . Planned conversion dialysis modality study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Coagulation activation</keyword>
</DOC>